Ken Griffin Myriad Genetics Inc Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Myriad Genetics Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 25,800 shares of MYGN stock, worth $631,068. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,800
Previous 28,400
9.15%
Holding current value
$631,068
Previous $543,000
1.29%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding MYGN
# of Institutions
191Shares Held
94.2MCall Options Held
280KPut Options Held
14.3K-
Black Rock Inc. New York, NY14.9MShares$364 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$245 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA8.06MShares$197 Million0.03% of portfolio
-
Camber Capital Management LP Boston, MA7.64MShares$187 Million3.99% of portfolio
-
State Street Corp Boston, MA5.4MShares$132 Million0.01% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $1.97B
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...